Lexicon banks third $10M Novo Nordisk milestone, $75M earned to date
What's the deal? Lexicon Pharmaceuticals (Nasdaq: LXRX) has earned a third $10 million milestone payment from Novo NordiskDealroom has a profile for this one. Try Dealroom → in 2026, triggered by a patient-dosing milestone in the Phase 1 trial of LX9851, an oral small-molecule ACSL5 inhibitor for obesity and related metabolic disorders. The payment lifts Lexicon's cumulative haul under the collaboration to $75 million.
Why now? Novo Nordisk began the Phase 1 trial in March 2026 in overweight or obese adults, testing safety, tolerability, pharmacokinetics, and pharmacodynamics. The study is expected to complete in the first quarter of 2027.
What's the endgame? Novo Nordisk holds an exclusive worldwide license for LX9851, signed in 2025, that makes Lexicon eligible for up to $1 billion in upfront and milestone payments, plus tiered royalties on future net sales. Preclinical data presented in 2024 showed enhanced weight and fat mass reductions when LX9851 was combined with semaglutide, the active ingredient in Novo's blockbuster obesity drugs.
What could go wrong? The $75 million earned is a fraction of the $1 billion on offer, and the drug remains in Phase 1. The bulk of the payout depends on advancing through later-stage development and commercialisation.
The signal: The steady milestone payments show Novo Nordisk pressing ahead on combination therapies as it defends its lead in the fast-growing obesity market. For Lexicon, the deal turns an early-stage asset into recurring, low-risk income while a deep-pocketed partner shoulders the development burden.
Read more: stocktitan.net
Image credit: Generated with Gemini
